197792-82-8Relevant articles and documents
ALPHA-5 BETA-1 INHIBITORS
-
, (2021/06/11)
The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.
R-Isomers of Arg-Gly-Asp (RGD) mimics as potent αvβ3 inhibitors
Nagarajan, Srinivasan R.,Devadas, Balekudru,Malecha, James W.,Lu, Hwang-Fun,Ruminski, Peter G.,Rico, Joseph G.,Rogers, Thomas E.,Marrufo, Laura D.,Collins, Joe T.,Kleine, H. Peter,Lantz, Melissa K.,Zhu, Jun,Green, Nawasa F.,Russell, Mark A.,Landis, Bryan H.,Miller, Lawrence M.,Meyer, Debra M.,Duffin, Tiffany D.,Engleman, V. Wayne,Finn, Mary B.,Freeman, Sandra K.,Griggs, David W.,Williams, Melanie L.,Nickols, Maureen A.,Pegg, Jodi A.,Shannon, Kristen E.,Steininger, Christina,Westlin, Marisa M.,Nickols, G. Alan,Keene, Jeffery L.
, p. 3783 - 3800 (2008/02/11)
The integrin αvβ3, vitronectin receptor, is expressed in a number of cell types and has been shown to mediate adhesion of osteoclasts to bone matrix, vascular smooth muscle cell migration, and angiogenesis. We recently disclosed the